Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017 - MarketsandMarkets

Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017

Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017 - MarketsandMarkets
Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017
Published Jul 01, 2013
350 pages — Published Jul 01, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:

The next generation sequencing market is rapidly evolving with a large number of developments taking place to increase accuracy and speed, and reduce costs of sequencing. It is the fastest-growing and most lucrative segment in the genomics space with an estimated growth of 16.3%. The global NGS market was valued at $1.3 billion in 2012 and is poised to reach $2.7 billion by 2017. By supporting genomics research, various government bodies like NHGRI (National Human Genome Research Institute, U.S.) and Biotechnology and Biological Sciences Research Council (BBSRC, U.K.) are increasing the adoption of high-throughput sequencing platforms.

The growth of the overall NGS market is driven by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. However, factors such as high reliability on grants and funding from the government, and decrease in capital expenditure from academic institutions are hindering the growth of the market. In addition, the interpretation of big data generated by sequencers and the subsequent storage and management of the analyzed data is still a challenge. Owing to the complexity of NGS technologies and data, standardization of the overall NGS workflow presents an unmet need. The opportunities for the growth of this market include developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions.

The NGS platforms market was dominated by Illumina in 2012, which accounted for the largest market share of 56%. Other companies with commercial platforms include Life Technologies (U.S.), 454 Roche (U.S.), and Pacific Biosciences (U.S.). The recently introduced Bench-top and NGS platforms will drive the market. Based on steps in the NGS workflow, the overall NGS market has three major segments, namely, pre-sequencing, NGS platforms and services, and NGS data analysis, storage and management.

The raw sequencing data generated by today's sequencers does not reflect on any meaningful information in itself. Also, open source tools for analyzing NGS data require adequate bioinformatics training. These factors open up huge opportunities for commercial NGS bioinformatics software, workbenches, and services, whose market is currently fragmented and has a relatively smaller size. Whole genome sequencing, targeted re-sequencing, de novo sequencing, RNA-Seq, ChIP-Seq and methyl-Seq are the major applications that use NGS data analysis tools and services. Key players like CLC bio (Denmark), Biomatters (New Zealand), Partek (U.S.), Genomatix (Germany), Knome (U.S.), and DNASTAR (U.S.) dominate this market space.

Next generation sequencing is set to revolutionize applied markets like diagnostics, drug discovery, biomarker discovery, personalized medicine, and agriculture and animals research. Research institutes and government bodies contribute the highest to the end-user market of NGS; however, the adoption rate in hospitals will increase in the near future due to cost effectiveness, high throughput, and sensitivity.

The NGS market will witness a whole new generation of sequencing platforms based on nanapore sequencing technology and fully integrated instruments that could perform all the NGS workflow steps.

Scope of the Report

This research report categorizes and analyzes the global NGS market on the basis of steps in the NGS workflow and NGS applications. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global NGS market, by steps in workflow

Pre-s

  
Source:
Document ID
BT 2074
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title
Table Of Contents

1 Introduction (Page No. - 24)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No. - 33)

3 Market Overview (Page No. - 38)
3.1 Introduction
3.2 Evolution
3.3 Market Segmentation
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Cost and Speed to Drive the Growth of NGS Technology
3.4.1.2 Substitution of Microarray Technology by NGS to Boost Market Growth
3.4.1.3 Embracement of NGS Technology by New Consumers to Propel the Market
3.4.1.4 Increase in Practice for New Scientific Applications to Boost the Growth
3.4.1.5 Research Laboratories and Academicians Promoting the Use of NGS
3.4.2 Restraints
3.4.2.1 High Reliability on Grants to Restrict Growth
3.4.2.2 Decrease in Capital Expenditure from Academic Institutes to Hinder the Sale of Platforms
3.4.2.3 Accuracy & Standardization, a Concern in Diagnostic Testing
3.4.3 Opportunities
3.4.3.1 Personalized Medicine & Biomarker Discovery Open Avenues for Investments in NGS Technology
3.4.3.2 Pre-sequencing, a High Growth Opportunity
3.4.3.3 Cloud Computing, a Prospective Service
3.4.4 Challenges
3.4.4.1 Interpretation of Complex Data from NGS Platforms
3.4.4.2 Designing of Sequencers as the Breadth of NGS Applications Increase
3.4.5 Market Trend
3.4.5.1 Shift of Focus Towards Third Generation Sequencing
3.4.6 Burning Issues
3.4.6.1 Data Storage, an Impediment for NGS Sequencing
3.4.6.2 Reduction in Cost to Sequence Human Genomes
3.4.7 Winning Imperative
3.4.7.1 Improved Collaborative Ties Between Industry and Academic & Research Institutes
3.5 Porter's Five Forces Analysis
3.5.1 Threat From New Entrants
3.5.2 Threat From Substitutes
3.5.3 Bargaining Power Of Buyers
3.5.4 Bargaining Power Of Suppliers
3.5.5 Competitive Rivalry Among Exisiting Firms
3.6 Value Chain
3.7 Technological Development Road-Map
3.7.1 Sanger Sequencing
3.7.2 Massively Parallel Sequencing (Next Generation Sequencing)
3.7.3 Single Molecule Real Time (SMRT) Sequencing
3.7.4 Nanopore Sequencing
3.8 Technological Trends
3.8.1 Nanopore Sequencing Technology
3.8.1.1 Oxford Nanopore Technologies
3.8.1.2 Genia Technologies
3.8.1.3 Electronic Biosciences
3.8.2 Sequencing By Hybridization Technology (GNUBIO)
3.8.3 GENIUS (Gene Electronic Nano-Integrated Ultra-Sensitive) Technology (GENAPSYS)
3.8.4 Lightning Terminator Sequencing Technology (LASERGEN)
3.8.5 Optical Nanopore Sequencing Technology (NOBLEGEN)
3.8.6 Nanowire Biosensor Sequencing Technology (QUANTUMDX)
3.9 End-User Analysis
3.9.1 Introduction
3.9.2 Research Centers, Academic & Government Institutes
3.9.2.1 NGS is a Research Driven Market, Hence the Highest Market Share
3.9.3 Hospitals & Clinics
3.9.3.1 Hospitals and Clinics to Grow at the Fastest Rate
3.9.4 Pharmaceutical & Biotechnology Companies
3.9.4.1 Targeted Therapy and Biomarker Research to Boost the Pharmaceutical & Biotechnolog

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017" Jul 01, 2013. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/Next-Generation-Sequencing-NGS-Market-Platforms-Illumina-HiSeq-MiSeq-Life-Technologies-Ion-Proton-PGM-454-Roche-Bioinformatics-RNA-Seq-ChIP-Seq-Pyrosequencing-SBS-SMRT-Diagnostics-Personalized-Medicine-Global-Forecast-to-2017-2144-173>
  
APA:
MarketsandMarkets. (2013). Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017 Jul 01, 2013. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/Next-Generation-Sequencing-NGS-Market-Platforms-Illumina-HiSeq-MiSeq-Life-Technologies-Ion-Proton-PGM-454-Roche-Bioinformatics-RNA-Seq-ChIP-Seq-Pyrosequencing-SBS-SMRT-Diagnostics-Personalized-Medicine-Global-Forecast-to-2017-2144-173>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.